ROSUVASTATIN Drug Patent Profile
✉ Email this page to a colleague
When do Rosuvastatin patents expire, and what generic alternatives are available?
Rosuvastatin is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms Co, Apotex, Aurobindo Pharma Ltd, Biocon Pharma, Cadila Pharms Ltd, Changzhou Pharm, Chartwell Rx, Glenmark Speclt, Hetero Labs Ltd V, Inventia, Lupin, Macleods Pharms Ltd, Mankind Pharma, MSN, Renata, Sandoz, Sciegen Pharms, Shandong, Strides Pharma, Sun Pharm, Sunshine, Teva Pharms Usa, Torrent, Umedica, Watson Labs Inc, Zhejiang Jingxin, and Zhejiang Yongtai. and is included in twenty-nine NDAs.
The generic ingredient in ROSUVASTATIN is rosuvastatin calcium. There are forty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the rosuvastatin calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rosuvastatin
A generic version of ROSUVASTATIN was approved as rosuvastatin calcium by WATSON LABS INC on April 29th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ROSUVASTATIN?
- What are the global sales for ROSUVASTATIN?
- What is Average Wholesale Price for ROSUVASTATIN?
Summary for ROSUVASTATIN
| US Patents: | 0 |
| Applicants: | 29 |
| NDAs: | 29 |
| Drug Prices: | Drug price information for ROSUVASTATIN |
| Drug Sales Revenues: | Drug sales revenues for ROSUVASTATIN |
| DailyMed Link: | ROSUVASTATIN at DailyMed |
See drug prices for ROSUVASTATIN
